FDA lifts its hold on vadastuximab talirine after Seattle Genetics adds new safeguards
A little more than two months after the FDA put a clinical hold on early-stage work of its armed antibody dubbed SGN-CD33A (vadastuximab talirine) in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
